UC Davis Comprehensive Cancer Center

Recent papers from UC Davis Comprehensive Cancer Center

1. Feature-Selection Stability and Functional Characterization of Sepsis-Related Transcriptomic Candidates Across Heterogeneous CohortsPathogens · 2026
2. Multiomic liquid biopsy: emerging applications in disease quantification, biomarker detection, molecular phenotyping, and cancer signal of origin predictionFrontiers in Oncology · 2026
3. Factors associated with breast, cervical and colorectal cancer screening participation in Inland Northern CaliforniaPreventive Oncology & Epidemiology · 2026
4. Src Homology Phosphatase 2 Disruption in Podocytes Attenuates Markers of Aristolochic Acid 1-Induced Renal Injury, Inflammation, and Fibrosis in MiceInternational Journal of Molecular Sciences · 2026
5. Advancing Sickle Cell Disease Care Through Collaboration: the HHS and ASH Registry Leaders' Roundtable InitiativeBlood Advances · 2026
6. Evaluation of Time to Metastasis After Prostatectomy as a Prognostic Factor in Patients With Metachronous mHSPC: A Secondary Analysis of the SWOG‐1216 Phase 3 TrialThe Prostate · 2026
7. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trialThe Lancet · 2026
8. Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025Cancer · 2026
9. Tobacco product use at the intersection of racial/ethnic and sexual orientation discrimination among California adults, 2022–2023: an observational studyInternational Journal for Equity in Health · 2026
10. Population pharmacokinetics for the CTLA‐4 modulator gotistobart in patients with advanced solid tumorsThe Journal of Clinical Pharmacology · 2026
11. Osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDClinical Lung Cancer · 2026
12. Convergent strategies for nanobody-mediated inhibition of an epoxide hydrolaseJournal of Structural Biology X · 2026
13. Trends and Predictors of Hematopoietic Cell Transplant Utilization for Human Immunodeficiency Virus-Lymphoma in California, 1991 to 2016Biology of Blood and Marrow Transplantation · 2026
14. Predictive Risk Model for Early Post-Treatment Acute Care Use in Adolescent and Young Adult Patients With CancerJCO Oncology Practice · 2026
15. Lenalidomide and rituximab for relapsed/refractory follicular lymphoma: a systematic review and meta-analysisBlood Cancer Journal · 2026
16. Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung CancerCancers · 2026
17. Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline UpdateJournal of Clinical Oncology · 2026
18. Continuous or Fixed-Duration Maintenance Therapy in Multiple MyelomaNew England Journal of Medicine · 2026
19. Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologyJCO Precision Oncology · 2026
20. Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignanciesENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2026